<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092363</url>
  </required_header>
  <id_info>
    <org_study_id>54F28-003</org_study_id>
    <nct_id>NCT02092363</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer</brief_title>
  <official_title>A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and&#xD;
      PK of OMP-54F28 when combined with paclitaxel and carboplatin. OMP-54F28 will be administered&#xD;
      IV on Days 1 of each 21-day cycle. Paclitaxel (175 mg/m2) and carboplatin (AUC = 5 mg/mL •&#xD;
      min) will be administered IV on Day 1 of each cycle. A total of 6 cycles of paclitaxel and&#xD;
      carboplatin will be given. Additional cycles may be given as per institutional standard of&#xD;
      care after discussion with the Medical Monitor. Treatment with OMP-54F28 will continue after&#xD;
      completion of treatment with paclitaxel and carboplatin. The planned dose levels of OMP-54F28&#xD;
      are 5 and 10 mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depending on safety in this study, additional lower or intermediate dose levels may be&#xD;
      evaluated. Depending on emerging safety data from the Phase 1a study 54F28-001 with&#xD;
      continuing dose escalation, additional higher dose levels of OMP-54F28 may be evaluated in&#xD;
      this study. Alternative dosing schedules of OMP-54F28 may be explored based on emerging&#xD;
      nonclinical and clinical data for safety, PD, PK and efficacy. The starting dose for a new&#xD;
      dosing schedule will be chosen to result in an AUC equivalent to the highest dose level that&#xD;
      cleared on the previously studied dosing schedule. No dose escalation of OMP-54F28 will be&#xD;
      allowed within a dose cohort.&#xD;
&#xD;
      Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined,&#xD;
      up to 10 patients may be enrolled in the cohort-expansion phase to better characterize the&#xD;
      safety, tolerability and PK of OMP-54F28 combined with paclitaxel and carboplatin. Up to&#xD;
      approximately 34 patients may be enrolled into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of OMP-54F28 in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer</measure>
    <time_frame>Subjects will be treated and observed for DLT through the end of the first cycle (from Day 0 - 21)</time_frame>
    <description>The maximum tolerated dose (MTD) will be determined in patients treated with OMP-54F28/paclitaxel/carboplatin (from Day 0 - 21)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Drug: OMP-54F28, Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMP-54F28, Paclitaxel and Carboplatin</intervention_name>
    <arm_group_label>Drug: OMP-54F28, Paclitaxel and Carboplatin</arm_group_label>
    <other_name>OMP-54F28</other_name>
    <other_name>Paclitaxel</other_name>
    <other_name>Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically documented ovarian, primary peritoneal or fallopian tube cancer&#xD;
&#xD;
          -  Recurrent platinum-sensitive disease, defined as disease progression ≥6 months after&#xD;
             completing a minimum of 4 cycles of a platinum-containing regimen&#xD;
&#xD;
          -  Availability of FFPE tumor tissue, either archival or obtained at study entry through&#xD;
             fresh biopsy&#xD;
&#xD;
             o Tumor tissue from fine needle aspiration is not acceptable.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤&#xD;
             1 prior to study entry&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Evaluable or measurable disease per RECIST v1.1&#xD;
&#xD;
          -  For women of childbearing potential, agreement to use two effective forms of&#xD;
             contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-epithelial ovarian carcinoma, including malignant mixed Mullerian tumors&#xD;
&#xD;
          -  Prior treatment with paclitaxel and carboplatin for recurrent platinum-sensitive&#xD;
             ovarian cancer&#xD;
&#xD;
          -  Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic&#xD;
             therapy, or herbal therapy within 3 weeks or 5 half-lives (for systemic agents),&#xD;
             whichever is shorter&#xD;
&#xD;
          -  Known hypersensitivity to any component of study treatments that resulted in drug&#xD;
             discontinuation&#xD;
&#xD;
          -  Grade ≥ 2 sensory neuropathy&#xD;
&#xD;
          -  Uncontrolled seizure disorder or active neurologic disease&#xD;
&#xD;
          -  Untreated brain metastases&#xD;
&#xD;
          -  Leptomeningeal disease as a manifestation of cancer&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
          -  Bisphosphonate therapy for symptomatic hypercalcemia&#xD;
&#xD;
          -  Known history of clinically significant liver disease, including active viral&#xD;
             hepatitis and cirrhosis&#xD;
&#xD;
          -  Significant intercurrent illness including, but not limited to, unstable angina&#xD;
             pectoris, and cardiac arrhythmia, or psychiatric illness/social situation that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Concurrent use of therapeutic warfarin&#xD;
&#xD;
          -  New York Heart Association Classification III or IV&#xD;
&#xD;
          -  Known clinically significant gastrointestinal disease including, but not limited to,&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to the first dose of study treatment or anticipation of need for major surgical&#xD;
             procedure during the course of the study&#xD;
&#xD;
          -  Osteoporosis based on a T-score of &lt;-2.5 at the left or right total hip, left or right&#xD;
             femoral neck or lumbar spine (L1-L4) as determined by DEXA scan&#xD;
&#xD;
          -  Bone metastases and one of the following:&#xD;
&#xD;
               -  Prior history of a pathologic fracture&#xD;
&#xD;
               -  Lytic lesion requiring an impending orthopedic intervention&#xD;
&#xD;
               -  Lack of treatment with a bisphosphonate or denosumab&#xD;
&#xD;
          -  Treatment with a thiazolidinedione PPAR gamma inhibitor; e.g. Actos® (pioglitazone)&#xD;
             and Avandia® (rosiglitzone)&#xD;
&#xD;
          -  Active treatment with an oral or IV glucocortocoid for ≥4 weeks at a daily dose&#xD;
             equivalent to or greater than 7.5 mg of oral prednisone&#xD;
&#xD;
          -  Fasting β-CTX of &gt;1000 pg/mL&#xD;
&#xD;
          -  Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Medical Center Laboratory</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox-Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-Sensitive Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

